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Abstract: From the patient perspective, medicine burden is more than the number of medicines, or
the complexity of medicine regimens they need to manage. Relationships between the number of
medicines, regimen complexity and patient perception of medicine burden are under-researched.
This cross-sectional study measured regimen complexity and determined how this and patient
perceived burden are affected by the therapeutic group. Regimen complexity was measured in
patients presenting prescriptions to six community pharmacies in South-East England. A sub-sample
(166) also completed the Living with Medicines Questionnaire which measures patient perceived
burden. The 492 patients were prescribed 2700 medicines (range 1 to 23). Almost half used at least one
non-oral formulation. Complexity was correlated strongly with the number of medicines (r = 0.94),
number of therapeutic groups (r = 0.84) and number of formulations (r = 0.73). Patients using
medicines for skin, eye and respiratory conditions had the highest complexity scores. Increasing the
number of medicines, frequency of dosing, number of non-oral formulations and number of different
therapeutic groups all increased medicine burden. Although cardiovascular medicines were the most
common medicines used by the majority of patients (60%), those for neurological, psychiatric and
gastro-intestinal conditions were most strongly associated with high burden. Studies are required
to determine medicine burden in different conditions, especially neurological conditions, including
chronic pain.
Keywords: medicine burden; regimen complexity; formulation; patient perception
1. Introduction
While the increasing number of prescription medicines required to manage chronic conditions is
acknowledged, the term medicine burden is used differently by different researchers. The biomedical
perspective of medicine burden is often interpreted simply as the number of medicines or daily “pills”
individual patients need to take to manage their conditions. Many studies have used the termmedicine
burden to describe the number of medicines used by specific cohorts within populations [1–4]. Such
studies suggest that a higher medicine burden may exist in certain medical conditions, for example a
study in Sweden suggests that patients with type II diabetes use more medicines than those without [1].
However, medicines are more complex than this, involving a wide range of formulations with
varying instructions, requiring different degrees of effort on the part of the patient to use correctly.
The difficulties patients experience in using medicines may vary with both the formulation and the
frequency and timing of dosing. A method of measuring the complexity of medicine regimens is
available, the Medication Regimen Complexity Index (MRCI) [5]. This instrument can be applied
to prescription data and could provide a more detailed measure of burden, than simply the number
of medicines, although MRCI score correlates highly with the number of medicines. The MRCI
gives higher weightings to formulations with greater difficulty in administration and to more
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frequent administration. Therefore, applying the MRCI requires full information about all the
medicines prescribed for an individual patient, including total number, dosage forms, dosing frequency
and additional directions. Although data are widely available on overall medicines prescribed in
England [6], relatively little data are available on the number of medicines used by individuals and
even less is known about the complexity of individual regimens. Data from Scotland published in 2014
found that 16.9% of adults were receiving four to nine medicines with 4.6% having ten or more [7].
A more recent English study involving 5213 patients over 60 years of age reported that almost a third
were using five or more medicines regularly, and only a fifth used none [8]. We found no studies which
measured regimen complexity in an English population.
The term burden has also been widely used in connection with medicines with anticholinergic
effects. A number of anticholinergic burden measures have been developed and used particularly to
assess cognitive function [9]. Most show that higher anticholinergic burden is associated with poorer
cognitive and functional outcomes.
However, all these measures of medicine burden are obtained from prescription details and do not
consider the impact of medicine use on the patient, from their perspective. More recently, an increasing
number of studies are exploring medicine burden from the patient perspective [10]. Medicine burden
is a large part of overall treatment burden, and given that medicines are the main method of treatment
for most medical conditions, they are the component of treatment burden most frequently identified
in qualitative studies [11]. These authors argue that treatment burden is associated with demands
placed upon patients, which is influenced by the number of medical conditions and the number of
medicines. They found that patients routinize and integrate their treatments into their daily lives,
perhaps prioritizing some over others, as well as using resources, such as social support, to help
manage their treatment burden [11]. Given the magnitude of medicines as treatments, the patient
perspective of medicine burden merits separate investigation from treatment burden. Medicine burden
from the patient perspective is not simply the number of medicines, or the complexity of medicine
regimens, but encompasses a range of domains.
We have developed and validated an instrument for measuring medicine burden: The Living
with Medicines Questionnaire (LMQ) [12,13]. The LMQ version 3 (LMQ-3) covers eight domains
which could be burdensome to individuals: relationships with health professionals, practicalities,
interferences, effectiveness, side effects, concerns, cost and autonomy. Our data suggest that
patients prescribed a higher number of medicines, using non-oral and multiple formulations and
with multiple daily dosage regimens perceive higher medicine burden [13]. However, medicine
complexity, as measured by the MRCI, is only weakly correlated with medicine burden [14,15].
Therefore, we set out to explore this association in greater detail. Our objectives were to measure the
complexity of prescribed medicine regimens in a sample of English patients and assess whether the
therapeutic group affects regimen complexity; to measure the self-reported burden of using long-term
medicines in this population and any associations with the medicine formulation, dosing frequency
and therapeutic group.
2. Materials and Methods
This cross-sectional survey involved patients presenting prescriptions to one of six community
pharmacies in the county of Kent, England, during October/November 2016. NHS Ethics approval
was obtained (Ref number: 16/YH/0413).
2.1. Inclusion Criteria
• Adults aged 18 years old or over
• Resident in England
• Using at least one long-term prescription medicine for at least 6 months
• Able to understand and read English
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2.2. Exclusion Criteria
• Under 18 years of age
• Not resident in England
• Presenting a prescription for another person
• Use of regular prescription medicine for less than 6 months
• Unable to understand English sufficiently to give informed consent or complete the questionnaire
A small multiple pharmacy company owning over 100 pharmacies in southeast England
supported the study. Six community pharmacies were selected to ensure a mix of deprivation and
the responsible pharmacist in each agreed to their pharmacy being included. In each pharmacy,
patients who had presented a prescription for dispensing were approached to take part by one of six
student researchers trained to ensure uniformity of approach. The study was explained verbally and, if
interested, screening questions were asked to ensure eligibility. Those who agreed were provided with
the LMQ-3 plus an envelope for its return and asked to complete a consent form, giving permission for
an anonymized list of their current prescription medicines to be made available from the pharmacist’s
electronic record. An information sheet was also provided, giving contact details and offering the
option to withdraw their consent at a later date.
The consent forms and questionnaires were coded with patient ID numbers to facilitate the
subsequent matching of data. On return of each completed consent form to the community pharmacist,
the pharmacist retrieved a list of current medicines, anonymized the list and added the ID number.
2.3. Instruments
The MRCI was applied to all individual retrieved prescription records, following the published
instructions [5]. In addition to the number of medicines, this allows the calculation of the overall
complexity score. Each item from each prescription was also categorized by the therapeutic class of
the medicine and the formulation type.
The LMQ-3 contains 41 statements covering eight domains related to medicine burden, using a
Likert-type scale with responses ranging from strongly agree to strongly disagree. The total LMQ-3
scores were calculated from the responses to these statements, using reverse scoring as required.
The scores were then categorized into low, moderate and high burden [13].
2.4. Data Analysis
The completed LMQ responses were matched to the prescription medicines lists. Associations
between variables were measured using Pearson’s or Spearman’s correlation coefficients, depending on
the type of data. Analysis of variance was used to determine differences in MRCI score across differing
levels of burden (low/moderate/high). Differences in LMQ scores in the presence or absence of
major therapeutic groups were assessed using t-tests. Linear regression analysis was performed using
regimen complexity (MRCI score) or perceived burden (LMQ score) as dependent variables, including
the presence of a medicine from each of the eight major therapeutic groups as the independent variables.
A significance level of p < 0.05 was accepted.
3. Results
3.1. Response Rates
In total, 776 patients were invited to participate and 582 (75.0%) agreed. Of the 582 participants,
521 (89.5%) consented to the pharmacist providing an anonymized copy of their prescription
medication record (PMR). Of the 521 PMRs analysed, 29 were subsequently excluded as the record was
incomplete or the patient was not using a long-term medicine. There were 268 (46.0%) patients who
returned the LMQ, although only 166 had both completed all 41 statements and also given permission
for the PMR to be provided.
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3.2. Medicines Prescribed
A total of 2700 medicines were prescribed for the 492 patients. The mean number of medicines per
patient was 5.49 (standard deviation 4.12), with a range of 1 to 23. Cardiovascular medicines were the
most frequently prescribed, followed by those acting on the central nervous system, gastro-intestinal
and respiratory systems, with these four major groups together constituting over 70% of all prescribed
medicines (Table 1).









Cardiovascular 813 (30.1%) 298 (60.6%) 2.7 (2; 1–8)
All central nervous
system drugs
595 (22.0%) 265 (53.9%) 2.2 (2; 1–11)
Psychiatry 261 (9.7%) 182 (37.0%) 1.4 (1; 1–8)
Neurology 334 (12.4%) 185 (37.6%) 1.8 (1; 1–9)
Gastro-intestinal drugs 275 (10.2%) 189 (38.4%) 1.5 (1; 1–5)
Respiratory drugs 246 (9.1%) 127 (25.8%) 2.0 (2; 1–6)
All endocrine drugs 266 (9.9%) 185 (37.6%) 1.4 (1; 1–5)
Diabetes 124 (4.6%) 75 (15.2%) 1.7 (1; 1–5)
Other endocrine drugs 123 (4.6%) 111 (22.6%) 1.1 (1; 1–3)
Musculo-skeletal 95 (3.5%) 82 (16.7%) 1.2 (1; 1–3)
Urinary/sex hormones 63 (2.3%) 51 (10.4%) 1.2 (1; 1–3)
Skin products 143 (5.3%) 78 (15.9%) 1.8 (1; 1–10)
Eye products 42 (1.6%) 33 (6.7%) 1.3 (1; 1–2)
Other 125 (4.4%) 123 (24.2%) 1.3 (1; 1–4)
Over 60% of the 492 patients whose prescription records were reviewed were using at least
one cardiovascular medicine and over half were using a central nervous system (CNS) medicine.
The number of prescribedmedicines per patient was the highest for cardiovascular, CNS and respiratory
drugs, and these patients were prescribed a median of two medicines from these groups. Almost a third
of patients (158; 32.1%) were prescribed medicines from four or more different major therapeutic areas.
Eighty-three patients (16.9%) were prescribed medicines from three major therapeutic areas, 129 (24.8%)
from two, and 121 patients (24.6%) used medicines from only one therapeutic area.
Almost all patients used oral solid dose formulations (477; 97.0%), but half (245; 49.8%) used other
formulations: a fifth used inhalers and more than a fifth used topical preparations (Table 2). While over
half (52.8%) used only one formulation, mostly oral, 153 (31.1%) used two formulations and 79 (16.1%)
used three or more different formulations, adding to the complexity of managing their regimens.
Table 2. Range of formulations prescribed.
Formulation Type Number of Prescriptions (% of total) Number of Patients (% of 492)
Oral solid dose 2132 (79.0%) 477 (97.0%)
Inhaler 192 (7.1%) 100 (20.3%)
Topical 183 (6.8%) 111 (22.6%)
Eye, ear and nasal 73 (2.7%) 59 (12.0%)
Other 120 (4.4%) 82 (16.7%)
Any formulation other than oral
solid dose
568 (21.0%) 245 (49.8%)
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3.3. Overall Medicine Complexity
The mean MRCI score was 14.1, with a range of 2–74. There was a very strong positive correlation
between the number of medicines and the MRCI score (Pearson’s r = 0.94), with higher MRCI scores
indicating greater regimen complexity. Complexity also correlated strongly with the number of
therapeutic groups of medicines patients used (Spearman’s r = 0.84; p < 0.001) and the number of
formulations used (r = 0.73). The mean MRCI scores were the highest in patients taking drugs for eye
(27.0; n = 33), skin (23.8; n = 78) and respiratory conditions (23.7; n = 107). Patients taking drugs for
cardiovascular conditions had the lowest mean MRCI scores (16.0; n = 298).
Linear regression analysis suggested that all major therapeutic groups contributed significantly
to the MRCI score (Table 3). The number of medicines prescribed within the therapeutic groups
all showed moderate positive correlations with the MRCI score, the strongest correlation being for
gastro-intestinal medicines.
Table 3. Relationships between the MRCI score and the therapeutic group.
Therapeutic
Group
Results of Linear Regression Analysis
Correlations between MRCI Score and
Number of Prescribed Medicines
within Therapeutic Groups *
B 95% CI p Value R Value p Value
Cardiovascular 5.20 3.55; 6.94 <0.001 0.35 <0.001
Respiratory 9.83 8.46;11.19 <0.001 0.34 <0.001
Gastro-intestinal 5.94 4.60; 7.27 <0.001 0.46 <0.001
Psychiatric 1.99 0.67; 3.30 0.003 0.31 <0.001
Neurological 5.53 4.13; 6.94 <0.001 0.39 <0.001
Endocrine 2.73 1.29; 4.18 <0.001 0.30 <0.001
Skin 7.41 5.74; 9.08 <0.001 0.34 0.002
Musculo-skeletal 3.39 1.72; 3.99 <0.001 Insufficient variation for analysis
Note: * Spearman’s correlation coefficient.
3.4. Patient Perceived Burden
Of the 166 participants who completed the LMQ, a third (55; 33.1%) had LMQ-3 scores indicating
a low level of perceived medicine burden, 53.6% (n = 89) had a moderate burden and 13.3% (n = 22)
had a high burden.
The MRCI scores, number of medicines prescribed, maximum number of dosing times
required per day, number of therapeutic groups and number of formulations all showed an
increasing association with increasing burden. However, with the exception of the dosing frequency,
the associations did not reach statistical significance (Table 4).
Table 4. Association of the various aspects of complexity with the perceived medicine burden.
Complexity Measure
Perceived Medicine Burden (LMQ Category)
p Value *
Low (55) Moderate (89) High (22)
MRCI score 10.5 ± 10.7 12.0 ± 9.5 16.2 ± 11.4 0.088
Number of medicines 3.7 ± 3.5 4.4 ± 3.8 5.8 ± 4.1 0.075
Number of formulations 1.5 ± 0.7 1.6 ± 0.8 1.9 ± 1.0 0.14
Maximum number of daily doses 2.2 ± 1.2 2.5 ± 1.3 3.1 ± 1.4 0.029
Number of therapeutic groups 2.4 ± 1.5 2.7 ± 1.7 3.2 ± 1.6 0.175
Note: * Analysis of variance.
Pharmacy 2019, 7, 18 6 of 9
The LMQ-3 scores were significantly higher in patients prescribed drugs for neurological,
gastro-intestinal and psychiatric conditions than in patients not prescribed drugs from these therapeutic
groups (Table 5). Linear regression suggested that drugs for neurological conditions contributed most
strongly to the LMQ scores.




Results of Linear Regression Analysis Mean LMQ-3 Score
B 95% CI p Value Present (n) Not Present (n) p Value *
Cardiovascular −3.28 −9.66; 3.09 0.311 93.7 (103) 95.6 (64) 0.521
Respiratory −0.02 −7.34; 7.30 0.996 97.4 (31) 93.7 (135) 0.319
Gastro-intestinal 5.19 −1.89; 12.27 0.150 100.2 (50) 91.8 (116) 0.007
Psychiatric 2.83 −3.60; 9.27 0.386 98.0 (59) 92.2 (126) 0.043
Neurological 7.05 0.07; 14.03 0.048 100.7 (55) 91.3 (130) 0.001
Endocrine −3.37 −10.43; 3.68 0.346 94.0 (97) 94.5 (129) 0.618
Skin −4.59 −13.31; 4.13 0.300 94.3 (21) 94.4 (145) 0.985
Musculo-skeletal 3.33 −4.79; 11.45 0.419 101.4 (28) 92.9 (138) 0.491
Note: * T-test.
Of the 22 patients with a high burden (LMQ score 110 or above), 21 (95%) used oral formulations,
seven (32%) inhaled formulations, six (27%) used a topical formulation and another six (27%) used
other formulations. Therefore, non-oral formulations were more common in this sub-group than in the
overall population of 492 patients. The proportions of patients using medicines for central nervous
system (73%), gastro-intestinal (45%), respiratory (36%), genito-urinary system (27%) and rheumatic
conditions (27%) were all higher than in the general population. However, the small numbers do not
permit the statistical evaluation of these findings.
4. Discussion
The findings provide some insight into the medicine burden in terms of the number, formulations
and complexity of medicines prescribed for a general population using community pharmacies
in England and also into the factors affecting patient perception of this burden. Four major
therapeutic areas (cardiovascular, gastro-intestinal, respiratory and centrally-acting) constituted the
large majority of prescribed medicines, and within three of these groups, patients were prescribed
an average of at least two medicines, but could receive up to eight different cardiovascular and
11 centrally-acting medicines.
Despite cardiovascular medicines being most commonly prescribed, they contributed less to
medicine regimen complexity than all other therapeutic groups. This is most likely due to the MRCI
scores taking into account the formulation and multiple daily dosing, since most cardiovascular
medicines are oral solid doses requiring once daily administration. Unsurprisingly, products for
respiratory, skin and eye conditions, which have both complex administration and require multiple
daily dosing, resulted in the highest MRCI scores.
The study confirmed that the overall number of medicines, frequency of dosing and the number
of non-oral formulations contributed to patient-reported medicine burden. The number of different
therapeutic groups was also found to be related to medicine burden and, therefore, the number of
medical conditions is also likely to be important. The therapeutic groups which appeared to be most
highly associated with patient-reported burden were gastro-intestinal and centrally-acting medicines,
particularly those for neurological conditions. The finding that medicines for neurological conditions
are associated with a higher burden is in line with a study in people with epilepsy which found
that they experienced a significantly higher burden than in the general population (M. Cashin-Cox;
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unpublished data). Studies are required in patients with other neurological and psychiatric conditions
to assess whether medicine burden is indeed high in these conditions. These studies should include
chronic pain, since medicines for rheumatic conditions as well as centrally-acting medicines were more
frequently found in those with the highest levels of burden.
The number of medicines has been shown to increase with the number of medical conditions in a
large cohort of Scottish patients [7], which found that cardiovascular conditions were associated with
the greatest number of medicines. Our findings are in line with this, and with prescribing data for
England [6], which show cardiovascular medicines to be the most commonly prescribed therapeutic
group. However, our study also highlights the contribution of other types of conditions to both the
number of medicines used and their complexity in individual patients.
It is increasingly important to obtain the patient perspective onmedicine burden and to learn more
about its association with medicine-taking behaviour. Studies show that medicine complexity may
be related to adherence [16], while small studies also indicate that some relationship exists between
patient perceived burden and adherence [17,18]. These studies contrast others which have found that
increasing the number of medicines prescribed has no effect on adherence and may thus be regarded
by health professionals as not problematic. Two studies in hypertension found that medicine burden
measured as the number of medicines was either unrelated to adherence [19] or that higher burden
was positively associated with both persistence and the medication possession ratio [20]. The authors
of the latter study suggested that concerns about medication burden should not deter clinicians from
adding more medicines to an individual’s regimen. Another study found that doctors were more
likely to initiate treatments for hypertension, diabetes and lipid-lowering drugs in patients already
using more drugs for other chronic diseases, also concluding that medicine burden was not a barrier
for initiating new medicines [21]. These studies show that the increasing burden of adding more
and more medicines to an already onerous regimen on the patient has, in the past, not always been
considered and, while adherence is an important measure of medicine-taking behavior, adherence
may be achieved at the expense of issues which are potentially burdensome. An awareness of regimen
complexity is also important when prescribing or reviewing medicines, since, as our study shows,
the dosing frequency and other aspects of regimen complexity can add to the patient’s burden.
This study is the first attempt to describe the types of medicines which may contribute to the
highest levels of medicine burden and relates these to different aspects of regimen complexity, which
may help to identify areas for further study. It provides a small snapshot of the patterns of medicines
used in only one geographical location in England. Moreover, the number of patients for whom
medicine burden could be compared to prescription regimen was small. Dispensed medicines may
not equate to medicines actually taken, but are more likely to reflect this than prescribed medicines
from medical records. No information on the actual medical conditions was available. Much more
work is needed to assess the factors that influence the relationship between the number of medicines,
regimen complexity, adherence and patient-perceived medicine burden.
5. Conclusions
While cardiovascular medicines constitute the highest number of medicines used, centrally-acting
and gastro-intestinal medicines contribute more to both complexity and medicine burden. Larger
studies are required to determine the medical conditions associated with greatest medicine burden.
Based on the current findings, future work should seek to determine medicine burden in patients
with specific medical conditions, especially mental health and neurological conditions, including
chronic pain.
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